JP2021513540A - 抗pd−1抗体及び抗ctla4抗体によるがんの処置方法 - Google Patents

抗pd−1抗体及び抗ctla4抗体によるがんの処置方法 Download PDF

Info

Publication number
JP2021513540A
JP2021513540A JP2020542952A JP2020542952A JP2021513540A JP 2021513540 A JP2021513540 A JP 2021513540A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2021513540 A JP2021513540 A JP 2021513540A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020542952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513540A5 (cg-RX-API-DMAC7.html
Inventor
ララ,マリカ
ジェイン,ロケッシュ
リー,モンヤオ
アルトゥーラ,レイチェル・アリソン
ツエ,アーチー・ガイ−チウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2021513540A publication Critical patent/JP2021513540A/ja
Publication of JP2021513540A5 publication Critical patent/JP2021513540A5/ja
Priority to JP2024000161A priority Critical patent/JP2024038250A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542952A 2018-02-13 2019-02-08 抗pd−1抗体及び抗ctla4抗体によるがんの処置方法 Ceased JP2021513540A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000161A JP2024038250A (ja) 2018-02-13 2024-01-04 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US62/630,038 2018-02-13
US201862732828P 2018-09-18 2018-09-18
US62/732,828 2018-09-18
US201862740741P 2018-10-03 2018-10-03
US62/740,741 2018-10-03
PCT/US2019/017188 WO2019160755A1 (en) 2018-02-13 2019-02-08 Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000161A Division JP2024038250A (ja) 2018-02-13 2024-01-04 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法

Publications (2)

Publication Number Publication Date
JP2021513540A true JP2021513540A (ja) 2021-05-27
JP2021513540A5 JP2021513540A5 (cg-RX-API-DMAC7.html) 2022-09-08

Family

ID=67620098

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542952A Ceased JP2021513540A (ja) 2018-02-13 2019-02-08 抗pd−1抗体及び抗ctla4抗体によるがんの処置方法
JP2024000161A Withdrawn JP2024038250A (ja) 2018-02-13 2024-01-04 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000161A Withdrawn JP2024038250A (ja) 2018-02-13 2024-01-04 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法

Country Status (11)

Country Link
US (1) US20210047409A1 (cg-RX-API-DMAC7.html)
EP (1) EP3752193A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021513540A (cg-RX-API-DMAC7.html)
KR (1) KR20200119845A (cg-RX-API-DMAC7.html)
CN (2) CN119792515A (cg-RX-API-DMAC7.html)
AU (2) AU2019222517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015915A8 (cg-RX-API-DMAC7.html)
CA (1) CA3090996A1 (cg-RX-API-DMAC7.html)
MA (1) MA51844A (cg-RX-API-DMAC7.html)
MX (1) MX2020008446A (cg-RX-API-DMAC7.html)
WO (1) WO2019160755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MA55316A (fr) * 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
JP2023515675A (ja) * 2020-03-05 2023-04-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
WO2021178611A1 (en) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
EP4373505A1 (en) * 2021-07-19 2024-05-29 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
MX2024004429A (es) * 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
CN113933520B (zh) * 2021-11-15 2023-06-20 邹灵龙 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof
AU2023338559A1 (en) * 2022-09-09 2025-03-27 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
CN118767127A (zh) * 2023-04-10 2024-10-15 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途
KR20260056175A (ko) * 2023-08-21 2026-04-24 아게누스 인코포레이티드 Ctla-4 저해제와 pd-1 저해제의 병용을 이용한 결장직장암의 치료 방법
TW202511295A (zh) * 2023-08-31 2025-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ctla4/tigit結合蛋白及其醫藥用途
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术(上海)股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2017523807A (ja) * 2014-08-01 2017-08-24 アケソ・バイオファーマ・インコーポレイテッド 抗ctla4モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
JP2017530950A (ja) * 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのpd−1アンタゴニストおよびalk阻害剤の併用
WO2017210624A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
DK3858859T3 (da) * 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331919A1 (en) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
EP3213768A1 (en) * 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
HUE062398T2 (hu) * 2016-06-02 2023-10-28 Bristol Myers Squibb Co PD-1 blokád nivolumabbal refrakter Hodgkin limfómában
KR102976378B1 (ko) * 2016-06-03 2026-06-11 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
CA3060695A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523807A (ja) * 2014-08-01 2017-08-24 アケソ・バイオファーマ・インコーポレイテッド 抗ctla4モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
JP2017530950A (ja) * 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのpd−1アンタゴニストおよびalk阻害剤の併用
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2017210624A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., 2017, VOL.77(13-SUPPLEMENT), CT065, JPN6022051032, ISSN: 0005318765 *
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, VOL.12, NO.11, PP.2777-2789, JPN6022051030, ISSN: 0005318766 *
JOUNAL OF IMMUNOTHERAPY OF CANCER, 2017, VOL.5, NO.43, PP.1-9, JPN6022051028, ISSN: 0005318764 *

Also Published As

Publication number Publication date
US20210047409A1 (en) 2021-02-18
KR20200119845A (ko) 2020-10-20
EP3752193A4 (en) 2022-02-23
RU2020129075A (ru) 2022-03-14
BR112020015915A2 (pt) 2020-12-15
CN111727056A (zh) 2020-09-29
AU2019222517A1 (en) 2020-08-13
MX2020008446A (es) 2020-09-28
AU2023208115A1 (en) 2024-01-18
CA3090996A1 (en) 2019-08-22
CN119792515A (zh) 2025-04-11
BR112020015915A8 (pt) 2023-01-31
MA51844A (fr) 2021-05-19
WO2019160755A1 (en) 2019-08-22
EP3752193A1 (en) 2020-12-23
JP2024038250A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
JP6812512B2 (ja) 癌を治療するためのpd−1アンタゴニストおよびido1阻害剤の組み合わせ
US20240026003A1 (en) Methods for treating cancer with anti-pd-1 antibodies
JP2024038250A (ja) 抗pd-1抗体及び抗ctla4抗体によるがんの処置方法
JP6586087B2 (ja) Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療
WO2018183408A1 (en) Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
EP4114464A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof
EP4136112A1 (en) Combination treatment for cancer
KR20210088640A (ko) 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법
JP2024513247A (ja) 抗pd-1抗体の皮下投与によるがんの治療方法
RU2825835C2 (ru) Способы лечения рака с помощью анти-PD-1-антител и анти-CTLA4-антител
RU2846266C2 (ru) Способы лечения злокачественного новообразования с использованием антител против pd-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240510

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260526